董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael D. Webb | 男 | Chairman of the Board | 65 | 5.86万美元 | 未持股 | 2023-08-01 |
| George Kegler | 男 | Director | 67 | 9.90万美元 | 未持股 | 2023-08-01 |
| Frank Pasqualone | 男 | Director | 67 | 4.88万美元 | 未持股 | 2023-08-01 |
| Marcus Schabacker | 男 | Director | 59 | 9.20万美元 | 未持股 | 2023-08-01 |
| Joseph Tucker | 男 | Chief Executive Officer and Director | 55 | 82.59万美元 | 未持股 | 2023-08-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph Tucker | 男 | Chief Executive Officer and Director | 55 | 82.59万美元 | 未持股 | 2023-08-01 |
| Peter Facchini | 男 | Chief Innovation Officer | 59 | 33.24万美元 | 未持股 | 2023-08-01 |
| Kevin Coveney | 男 | Chief Financial Officer | 59 | 未披露 | 未持股 | 2023-08-01 |
董事简历
中英对照 | 中文 | 英文- Michael D. Webb
-
Michael D. Webb，自2022年6月13日起担任公司非雇员董事，自2022年11月起担任董事会主席。Webb先生是Epion Therapeutics，Inc.的总裁兼首席执行官，也是该公司董事会成员，自2017年以来一直担任该职务。他自2022年起担任iQure Pharma Inc.董事，自2021年起担任GMDx Genomics董事，自2018年起担任Videokawa董事，自2012年起担任DeuteRx，LLC董事。他一直是生物技术公司的创始人和首席执行官，通过风险融资和纳斯达克 IPO从种子轮融资。Webb先生的职业生涯始于Booz，Allen & Hamilton在芝加哥的办公室，专攻医疗保健和生命科学，随后在CIBA-Geigy（现为诺华）担任高级副总裁。韦布拥有堪萨斯大学生物化学和经济学学士学位，并以优异成绩获得英国萨塞克斯大学国际关系硕士学位。此外，他还拥有家乐氏管理学院的MBA学位，主修医疗保健管理。
Michael D. Webb,has served as a non-employee director of the Company since June 13, 2022 and has served as Chairman of the Board since November 2022. Mr. Webb is the President and Chief Executive Officer of Epion Therapeutics, Inc. and a member of its board of directors, positions he has held since 2017. He has served as a director at iQure Pharma Inc. since 2022, at GMDx Genomics since 2021, at Videokawa since 2018, and at DeuteRx, LLC since 2012. He has been a founder and Chief Executive Officer of biotechnology companies, taking them from seed round funding through venture financing and Nasdaq IPO. Mr. Webb began his career in Booz, Allen & Hamilton's Chicago office, specializing in healthcare and life sciences and subsequently at CIBA-Geigy (now Novartis) where he was last a Senior Vice President. Mr. Webb holds Bachelor's degrees in Biochemistry and Economics from the University of Kansas, summa cum laude and an MA in International Relations from Sussex University in the UK. In addition, he holds an MBA degree from Kellogg School of Management with a concentration in healthcare management. - Michael D. Webb，自2022年6月13日起担任公司非雇员董事，自2022年11月起担任董事会主席。Webb先生是Epion Therapeutics，Inc.的总裁兼首席执行官，也是该公司董事会成员，自2017年以来一直担任该职务。他自2022年起担任iQure Pharma Inc.董事，自2021年起担任GMDx Genomics董事，自2018年起担任Videokawa董事，自2012年起担任DeuteRx，LLC董事。他一直是生物技术公司的创始人和首席执行官，通过风险融资和纳斯达克 IPO从种子轮融资。Webb先生的职业生涯始于Booz，Allen & Hamilton在芝加哥的办公室，专攻医疗保健和生命科学，随后在CIBA-Geigy（现为诺华）担任高级副总裁。韦布拥有堪萨斯大学生物化学和经济学学士学位，并以优异成绩获得英国萨塞克斯大学国际关系硕士学位。此外，他还拥有家乐氏管理学院的MBA学位，主修医疗保健管理。
- Michael D. Webb,has served as a non-employee director of the Company since June 13, 2022 and has served as Chairman of the Board since November 2022. Mr. Webb is the President and Chief Executive Officer of Epion Therapeutics, Inc. and a member of its board of directors, positions he has held since 2017. He has served as a director at iQure Pharma Inc. since 2022, at GMDx Genomics since 2021, at Videokawa since 2018, and at DeuteRx, LLC since 2012. He has been a founder and Chief Executive Officer of biotechnology companies, taking them from seed round funding through venture financing and Nasdaq IPO. Mr. Webb began his career in Booz, Allen & Hamilton's Chicago office, specializing in healthcare and life sciences and subsequently at CIBA-Geigy (now Novartis) where he was last a Senior Vice President. Mr. Webb holds Bachelor's degrees in Biochemistry and Economics from the University of Kansas, summa cum laude and an MA in International Relations from Sussex University in the UK. In addition, he holds an MBA degree from Kellogg School of Management with a concentration in healthcare management.
- George Kegler
-
George Kegler，自2020年12月30日起担任公司非雇员董事。Kegler先生于2013年1月至2019年6月受雇于马林克罗制药，于2018年12月至2019年5月担任执行副总裁兼临时首席财务官，负责全球财务职能，2016年11月至2018年11月担任执行委员会成员，2016年7月至2016年10月担任财务副总裁（临时）和财务副总裁，2013年1月至2016年6月担任财务副总裁。自2019年6月至2020年3月结束，他担任过多个咨询职位。Kegler先生在财务规划和分析、公司财务、控制和业务发展方面拥有40年的经验。在此之前，Kegler先生曾担任万灵科多个部门的商业金融副总裁，同时也是该公司特种仿制药业务的临时总裁。在加入万灵科之前，他是Convatec的首席财务官，Convatec是一家私人股本公司，从百时美施贵宝手中收购。他曾在百时美施贵宝担任多个财务职务，包括商业、国际、技术运营、研发以及内部控制助理总监。Kegler先生拥有密苏里大学会计学学士学位和圣路易斯大学MBA学位，并在密苏里完成了注册会计师考试。
George Kegler,has served as a non-employee director of the Company since December 30, 2020. Mr. Kegler was employed by Mallinckrodt Pharmaceuticals from January 2013 to June 2019, serving as the Executive Vice President and Chief Financial Officer, Interim from December 2018 to May 2019, where he had responsibility for the global finance function and was a member of the executive committee, Vice President Finance from November 2016 to November 2018, President Specialty Generics (Interim) and Vice President Finance from July 2016 to October 2016, and Vice President, Finance from January 2013 to June 2016. He has served in various consulting roles since June 2019, which ended in March 2020. Mr. Kegler has 40 years of experience in financial planning and analysis, corporate finance, controllership and business development. Previously Mr. Kegler served as the Vice President of Commercial Finance for various businesses within Mallinckrodt and was also interim President of the company's specialty generics business. Prior to joining Mallinckrodt, he was the Chief Financial Officer for Convatec, a private equity-owned company that was purchased from Bristol-Myers Squibb. He worked in various finance roles within Bristol-Myers Squibb including commercial, International, technical operations, research & development as well as the assistant controller of internal controls. Mr. Kegler holds a bachelor's degree in accounting from the University of Missouri, an MBA from Saint Louis University and completed the Certified Public Accountant exam in Missouri. - George Kegler，自2020年12月30日起担任公司非雇员董事。Kegler先生于2013年1月至2019年6月受雇于马林克罗制药，于2018年12月至2019年5月担任执行副总裁兼临时首席财务官，负责全球财务职能，2016年11月至2018年11月担任执行委员会成员，2016年7月至2016年10月担任财务副总裁（临时）和财务副总裁，2013年1月至2016年6月担任财务副总裁。自2019年6月至2020年3月结束，他担任过多个咨询职位。Kegler先生在财务规划和分析、公司财务、控制和业务发展方面拥有40年的经验。在此之前，Kegler先生曾担任万灵科多个部门的商业金融副总裁，同时也是该公司特种仿制药业务的临时总裁。在加入万灵科之前，他是Convatec的首席财务官，Convatec是一家私人股本公司，从百时美施贵宝手中收购。他曾在百时美施贵宝担任多个财务职务，包括商业、国际、技术运营、研发以及内部控制助理总监。Kegler先生拥有密苏里大学会计学学士学位和圣路易斯大学MBA学位，并在密苏里完成了注册会计师考试。
- George Kegler,has served as a non-employee director of the Company since December 30, 2020. Mr. Kegler was employed by Mallinckrodt Pharmaceuticals from January 2013 to June 2019, serving as the Executive Vice President and Chief Financial Officer, Interim from December 2018 to May 2019, where he had responsibility for the global finance function and was a member of the executive committee, Vice President Finance from November 2016 to November 2018, President Specialty Generics (Interim) and Vice President Finance from July 2016 to October 2016, and Vice President, Finance from January 2013 to June 2016. He has served in various consulting roles since June 2019, which ended in March 2020. Mr. Kegler has 40 years of experience in financial planning and analysis, corporate finance, controllership and business development. Previously Mr. Kegler served as the Vice President of Commercial Finance for various businesses within Mallinckrodt and was also interim President of the company's specialty generics business. Prior to joining Mallinckrodt, he was the Chief Financial Officer for Convatec, a private equity-owned company that was purchased from Bristol-Myers Squibb. He worked in various finance roles within Bristol-Myers Squibb including commercial, International, technical operations, research & development as well as the assistant controller of internal controls. Mr. Kegler holds a bachelor's degree in accounting from the University of Missouri, an MBA from Saint Louis University and completed the Certified Public Accountant exam in Missouri.
- Frank Pasqualone
-
Frank Pasqualone，自2022年7月13日起担任本公司非雇员董事。Pasqualone先生自2020年11月起担任Theravance Biopharma高级副总裁兼首席商务官，并于2014年6月加入Theravance Biopharma，担任运营高级副总裁，负责从亚邦丝医疗剥离。Pasqualone先生自2014年1月起担任亚邦丝医疗运营高级副总裁。2010年至2012年，他在百时美施贵宝（BMS）担任拉丁美洲、中东和非洲洲际区域总裁，2009年至2010年担任南欧总裁。帕斯夸隆在BMS工作了25年，在美国和全球担任高级管理职位。在美国，他负责肿瘤学/病毒学业务，并领导糖尿病业务的营销团队。离开百时美施贵宝后，在加入Theravance之前，Pasqualone先生是一名兼职顾问。帕斯夸隆拥有代顿大学的工商管理硕士学位和俄亥俄州鲍灵格林州立大学的市场营销学士学位。
Frank Pasqualone,has served as a non-employee director of the Company since July 13, 2022. Mr. Pasqualone has served as Senior Vice President, Chief Business Officer of Theravance Biopharma, Inc. since November 2020 and joined Theravance Biopharma as Senior Vice President, Operations in June 2014 in connection with its spin-off from Innoviva. Mr. Pasqualone held the position of Senior Vice President, Operations at Innoviva since January 2014. From 2010 to 2012, he served as President of Intercontinental Region: Latin America, Middle East and Africa and also as President of Southern Europe from 2009 to 2010, at Bristol-Myers Squibb (BMS). Over a 25-year period with BMS, Mr. Pasqualone held senior management positions in the U.S. and globally. In the U.S., he was responsible for the Oncology/Virology business and led the marketing group in the Diabetes business. After leaving Bristol-Myers Squibb and prior to joining Theravance, Mr. Pasqualone was self-employed as a part-time consultant. Mr. Pasqualone holds an M.B.A. from University of Dayton and a B.S. in Marketing from Bowling Green State University in Ohio. - Frank Pasqualone，自2022年7月13日起担任本公司非雇员董事。Pasqualone先生自2020年11月起担任Theravance Biopharma高级副总裁兼首席商务官，并于2014年6月加入Theravance Biopharma，担任运营高级副总裁，负责从亚邦丝医疗剥离。Pasqualone先生自2014年1月起担任亚邦丝医疗运营高级副总裁。2010年至2012年，他在百时美施贵宝（BMS）担任拉丁美洲、中东和非洲洲际区域总裁，2009年至2010年担任南欧总裁。帕斯夸隆在BMS工作了25年，在美国和全球担任高级管理职位。在美国，他负责肿瘤学/病毒学业务，并领导糖尿病业务的营销团队。离开百时美施贵宝后，在加入Theravance之前，Pasqualone先生是一名兼职顾问。帕斯夸隆拥有代顿大学的工商管理硕士学位和俄亥俄州鲍灵格林州立大学的市场营销学士学位。
- Frank Pasqualone,has served as a non-employee director of the Company since July 13, 2022. Mr. Pasqualone has served as Senior Vice President, Chief Business Officer of Theravance Biopharma, Inc. since November 2020 and joined Theravance Biopharma as Senior Vice President, Operations in June 2014 in connection with its spin-off from Innoviva. Mr. Pasqualone held the position of Senior Vice President, Operations at Innoviva since January 2014. From 2010 to 2012, he served as President of Intercontinental Region: Latin America, Middle East and Africa and also as President of Southern Europe from 2009 to 2010, at Bristol-Myers Squibb (BMS). Over a 25-year period with BMS, Mr. Pasqualone held senior management positions in the U.S. and globally. In the U.S., he was responsible for the Oncology/Virology business and led the marketing group in the Diabetes business. After leaving Bristol-Myers Squibb and prior to joining Theravance, Mr. Pasqualone was self-employed as a part-time consultant. Mr. Pasqualone holds an M.B.A. from University of Dayton and a B.S. in Marketing from Bowling Green State University in Ohio.
- Marcus Schabacker
-
Marcus Schabacker自2020年12月30日起担任Enveric Biosciences, Inc.的非雇员董事。自2018年1月以来，Schabacker博士一直担任ECRI Institute的总裁兼首席执行官。ECRI Institute是一个非营利组织，拥有500名员工和8000万美元的运营预算，致力于推进全球的基于证据的有效医疗保健。在加入ECRI之前，Schabacker博士曾在Baxter Healthcare Corporation工作，从2015年7月至2017年5月担任企业副总裁兼首席科学官，从2014年3月至2017年5月担任执行质量委员会主席，从2014年7月至2015年7月担任医疗产品首席科学官，以及从2011年3月至2014年7月担任研发副总裁。在临床工作和担任行业思想领袖期间，Schabacker博士专注于患者安全和提高患者护理质量。
Marcus Schabacker,has served as a non-employee director of the Company since December 30, 2020. Since January 2018, Dr. Schabacker has served as President and Chief Executive Officer of the ECRI Institute, a non-profit organization with 500 employees and an operating budget of $80 million focusing on advancing evidenced-based, effective healthcare globally. Prior to joining ECRI, Dr. Schabacker worked at Baxter Healthcare Corporation, serving as Corporate Vice President and Chief Scientific Officer from July 2015 to May 2017, chairman of the executive quality council from March 2014 to May 2017, Chief Scientific Officer, Medical Products from July 2014 to July 2015, and Vice President, R&D, Medical Products from March 2011 to July 2014. During his clinical years, and his time as an industry thought leader, Dr. Schabacker was focused on patient safety and enhancing patient care. - Marcus Schabacker自2020年12月30日起担任Enveric Biosciences, Inc.的非雇员董事。自2018年1月以来，Schabacker博士一直担任ECRI Institute的总裁兼首席执行官。ECRI Institute是一个非营利组织，拥有500名员工和8000万美元的运营预算，致力于推进全球的基于证据的有效医疗保健。在加入ECRI之前，Schabacker博士曾在Baxter Healthcare Corporation工作，从2015年7月至2017年5月担任企业副总裁兼首席科学官，从2014年3月至2017年5月担任执行质量委员会主席，从2014年7月至2015年7月担任医疗产品首席科学官，以及从2011年3月至2014年7月担任研发副总裁。在临床工作和担任行业思想领袖期间，Schabacker博士专注于患者安全和提高患者护理质量。
- Marcus Schabacker,has served as a non-employee director of the Company since December 30, 2020. Since January 2018, Dr. Schabacker has served as President and Chief Executive Officer of the ECRI Institute, a non-profit organization with 500 employees and an operating budget of $80 million focusing on advancing evidenced-based, effective healthcare globally. Prior to joining ECRI, Dr. Schabacker worked at Baxter Healthcare Corporation, serving as Corporate Vice President and Chief Scientific Officer from July 2015 to May 2017, chairman of the executive quality council from March 2014 to May 2017, Chief Scientific Officer, Medical Products from July 2014 to July 2015, and Vice President, R&D, Medical Products from March 2011 to July 2014. During his clinical years, and his time as an industry thought leader, Dr. Schabacker was focused on patient safety and enhancing patient care.
- Joseph Tucker
-
Joseph Tucker，自2021年9月16日起担任Enveric Biosciences, Inc.首席执行官兼董事。在加入公司之前，Tucker博士是MagicMed Industries Inc.的首席执行官、总裁和董事，从该公司于2020年5月成立到2021年9月被公司收购。塔克博士于2019年4月至2020年3月担任多伦多证交所上市公司Willow Biosciences Inc.的执行主席。从2014年3月到2019年4月，塔克博士担任Epimeron公司的首席执行官、总裁和董事。Epimeron公司于2019年4月与BioCan Technologies公司合并，成为Willow Biosciences公司。2007年至2014年，塔克博士在其他几家私营生物技术公司担任总裁、首席执行官和首席财务官职务，包括VirTech Bio公司、Taiga Bioactives公司、SolAeroMed公司和Pharmavation公司。从2001年1月到2007年1月，塔克博士担任Stem Cell Therapeutics公司的首席执行官、总裁和董事。Stem Cell Therapeutics是一家在多伦多证交所上市的上市生物技术公司。在进入领先的生物技术公司之前，塔克博士是两家投资银行的医疗保健分析师，还在一所大学的技术转让办公室担任技术商业化职务。塔克博士在卡尔加里大学获得生物化学和分子生物学博士学位。
Joseph Tucker,has served as Enveric Biosciences, Inc. Chief Executive Officer and Director since September 16, 2021. Prior to joining the Company, Dr. Tucker was the Chief Executive Officer, President and Director of MagicMed Industries Inc., from its founding in May 2020 until its acquisition by the Company in September 2021. Dr. Tucker was the Executive Chairman of Willow Biosciences Inc., a TSX-listed public company, from April 2019 to March 2020. From March 2014 until April 2019, Dr. Tucker was the Chief Executive Officer, President and Director of Epimeron Inc., which amalgamated with BioCan Technologies Inc. in April 2019 to become Willow Biosciences, Inc. Between 2007 and 2014, Dr. Tucker held President, Chief Executive Officer, and Chief Financial Officer roles in several other private biotechnology companies including VirTech Bio, Inc., Taiga Bioactives Inc., SolAeroMed, Inc., and Pharmavation, Inc. From January 2001 until January 2007, Dr. Tucker was Chief Executive Officer, President and Director of Stem Cell Therapeutics, a TSX-listed public biotechnology company. Prior to leading biotechnology companies, Dr. Tucker was a healthcare analyst with two investment banks and also served in a technology commercialization capacity for a university technology transfer office. Dr. Tucker received his Ph.D. in Biochemistry and Molecular Biology from the University of Calgary. - Joseph Tucker，自2021年9月16日起担任Enveric Biosciences, Inc.首席执行官兼董事。在加入公司之前，Tucker博士是MagicMed Industries Inc.的首席执行官、总裁和董事，从该公司于2020年5月成立到2021年9月被公司收购。塔克博士于2019年4月至2020年3月担任多伦多证交所上市公司Willow Biosciences Inc.的执行主席。从2014年3月到2019年4月，塔克博士担任Epimeron公司的首席执行官、总裁和董事。Epimeron公司于2019年4月与BioCan Technologies公司合并，成为Willow Biosciences公司。2007年至2014年，塔克博士在其他几家私营生物技术公司担任总裁、首席执行官和首席财务官职务，包括VirTech Bio公司、Taiga Bioactives公司、SolAeroMed公司和Pharmavation公司。从2001年1月到2007年1月，塔克博士担任Stem Cell Therapeutics公司的首席执行官、总裁和董事。Stem Cell Therapeutics是一家在多伦多证交所上市的上市生物技术公司。在进入领先的生物技术公司之前，塔克博士是两家投资银行的医疗保健分析师，还在一所大学的技术转让办公室担任技术商业化职务。塔克博士在卡尔加里大学获得生物化学和分子生物学博士学位。
- Joseph Tucker,has served as Enveric Biosciences, Inc. Chief Executive Officer and Director since September 16, 2021. Prior to joining the Company, Dr. Tucker was the Chief Executive Officer, President and Director of MagicMed Industries Inc., from its founding in May 2020 until its acquisition by the Company in September 2021. Dr. Tucker was the Executive Chairman of Willow Biosciences Inc., a TSX-listed public company, from April 2019 to March 2020. From March 2014 until April 2019, Dr. Tucker was the Chief Executive Officer, President and Director of Epimeron Inc., which amalgamated with BioCan Technologies Inc. in April 2019 to become Willow Biosciences, Inc. Between 2007 and 2014, Dr. Tucker held President, Chief Executive Officer, and Chief Financial Officer roles in several other private biotechnology companies including VirTech Bio, Inc., Taiga Bioactives Inc., SolAeroMed, Inc., and Pharmavation, Inc. From January 2001 until January 2007, Dr. Tucker was Chief Executive Officer, President and Director of Stem Cell Therapeutics, a TSX-listed public biotechnology company. Prior to leading biotechnology companies, Dr. Tucker was a healthcare analyst with two investment banks and also served in a technology commercialization capacity for a university technology transfer office. Dr. Tucker received his Ph.D. in Biochemistry and Molecular Biology from the University of Calgary.
高管简历
中英对照 | 中文 | 英文- Joseph Tucker
Joseph Tucker，自2021年9月16日起担任Enveric Biosciences, Inc.首席执行官兼董事。在加入公司之前，Tucker博士是MagicMed Industries Inc.的首席执行官、总裁和董事，从该公司于2020年5月成立到2021年9月被公司收购。塔克博士于2019年4月至2020年3月担任多伦多证交所上市公司Willow Biosciences Inc.的执行主席。从2014年3月到2019年4月，塔克博士担任Epimeron公司的首席执行官、总裁和董事。Epimeron公司于2019年4月与BioCan Technologies公司合并，成为Willow Biosciences公司。2007年至2014年，塔克博士在其他几家私营生物技术公司担任总裁、首席执行官和首席财务官职务，包括VirTech Bio公司、Taiga Bioactives公司、SolAeroMed公司和Pharmavation公司。从2001年1月到2007年1月，塔克博士担任Stem Cell Therapeutics公司的首席执行官、总裁和董事。Stem Cell Therapeutics是一家在多伦多证交所上市的上市生物技术公司。在进入领先的生物技术公司之前，塔克博士是两家投资银行的医疗保健分析师，还在一所大学的技术转让办公室担任技术商业化职务。塔克博士在卡尔加里大学获得生物化学和分子生物学博士学位。
Joseph Tucker,has served as Enveric Biosciences, Inc. Chief Executive Officer and Director since September 16, 2021. Prior to joining the Company, Dr. Tucker was the Chief Executive Officer, President and Director of MagicMed Industries Inc., from its founding in May 2020 until its acquisition by the Company in September 2021. Dr. Tucker was the Executive Chairman of Willow Biosciences Inc., a TSX-listed public company, from April 2019 to March 2020. From March 2014 until April 2019, Dr. Tucker was the Chief Executive Officer, President and Director of Epimeron Inc., which amalgamated with BioCan Technologies Inc. in April 2019 to become Willow Biosciences, Inc. Between 2007 and 2014, Dr. Tucker held President, Chief Executive Officer, and Chief Financial Officer roles in several other private biotechnology companies including VirTech Bio, Inc., Taiga Bioactives Inc., SolAeroMed, Inc., and Pharmavation, Inc. From January 2001 until January 2007, Dr. Tucker was Chief Executive Officer, President and Director of Stem Cell Therapeutics, a TSX-listed public biotechnology company. Prior to leading biotechnology companies, Dr. Tucker was a healthcare analyst with two investment banks and also served in a technology commercialization capacity for a university technology transfer office. Dr. Tucker received his Ph.D. in Biochemistry and Molecular Biology from the University of Calgary.- Joseph Tucker，自2021年9月16日起担任Enveric Biosciences, Inc.首席执行官兼董事。在加入公司之前，Tucker博士是MagicMed Industries Inc.的首席执行官、总裁和董事，从该公司于2020年5月成立到2021年9月被公司收购。塔克博士于2019年4月至2020年3月担任多伦多证交所上市公司Willow Biosciences Inc.的执行主席。从2014年3月到2019年4月，塔克博士担任Epimeron公司的首席执行官、总裁和董事。Epimeron公司于2019年4月与BioCan Technologies公司合并，成为Willow Biosciences公司。2007年至2014年，塔克博士在其他几家私营生物技术公司担任总裁、首席执行官和首席财务官职务，包括VirTech Bio公司、Taiga Bioactives公司、SolAeroMed公司和Pharmavation公司。从2001年1月到2007年1月，塔克博士担任Stem Cell Therapeutics公司的首席执行官、总裁和董事。Stem Cell Therapeutics是一家在多伦多证交所上市的上市生物技术公司。在进入领先的生物技术公司之前，塔克博士是两家投资银行的医疗保健分析师，还在一所大学的技术转让办公室担任技术商业化职务。塔克博士在卡尔加里大学获得生物化学和分子生物学博士学位。
- Joseph Tucker,has served as Enveric Biosciences, Inc. Chief Executive Officer and Director since September 16, 2021. Prior to joining the Company, Dr. Tucker was the Chief Executive Officer, President and Director of MagicMed Industries Inc., from its founding in May 2020 until its acquisition by the Company in September 2021. Dr. Tucker was the Executive Chairman of Willow Biosciences Inc., a TSX-listed public company, from April 2019 to March 2020. From March 2014 until April 2019, Dr. Tucker was the Chief Executive Officer, President and Director of Epimeron Inc., which amalgamated with BioCan Technologies Inc. in April 2019 to become Willow Biosciences, Inc. Between 2007 and 2014, Dr. Tucker held President, Chief Executive Officer, and Chief Financial Officer roles in several other private biotechnology companies including VirTech Bio, Inc., Taiga Bioactives Inc., SolAeroMed, Inc., and Pharmavation, Inc. From January 2001 until January 2007, Dr. Tucker was Chief Executive Officer, President and Director of Stem Cell Therapeutics, a TSX-listed public biotechnology company. Prior to leading biotechnology companies, Dr. Tucker was a healthcare analyst with two investment banks and also served in a technology commercialization capacity for a university technology transfer office. Dr. Tucker received his Ph.D. in Biochemistry and Molecular Biology from the University of Calgary.
- Peter Facchini
Peter Facchini，自2021年9月加入公司以来一直担任Enveric Biosciences, Inc.首席创新官。Facchini博士自1995年起担任卡尔加里大学生物科学系植物生物化学教授，期间担任加拿大植物代谢过程生物技术研究主席，2019年Parex资源创新研究员，获得2021年科学创新学院卓越奖，并入围2022年艾伯塔省科学、技术和领导力（ASTech）奖。在加入公司之前，Facchini博士是Epimeron公司、Willow Biosciences公司和MagicMed Industries公司的联合创始人和首席科学官。Facchini博士发表了170多篇同行评议的科学论文，并共同发明了涉及50多项专利的创新。Facchini博士是天然产物代谢生化和生物技术领域的国际领导者。
Peter Facchini,has served as Enveric Biosciences, Inc. Chief Innovation Officer since joining the Company in September 2021. Dr. Facchini has been a Professor of Plant Biochemistry in the Department of Biological Sciences at the University of Calgary since 1995, during which he held the Canada Research Chair in Plant Metabolic Processes Biotechnology, was a 2019 Parex Resources Innovation Fellow, received the 2021 Faculty of Science Innovation Excellence Award, and was a finalist for the 2022 Alberta Science, Technology and Leadership (ASTech) award. Prior to joining the Company, Dr. Facchini co-founded and was the Chief Scientific Officer of Epimeron Inc., Willow Biosciences Inc. and MagicMed Industries Inc. Dr. Facchini has published over 170 peer-reviewed scientific papers and co-invented innovations covered by more than 50 patents. Dr. Facchini is an international leader in the fields of natural product metabolic biochemistry and biotechnology.- Peter Facchini，自2021年9月加入公司以来一直担任Enveric Biosciences, Inc.首席创新官。Facchini博士自1995年起担任卡尔加里大学生物科学系植物生物化学教授，期间担任加拿大植物代谢过程生物技术研究主席，2019年Parex资源创新研究员，获得2021年科学创新学院卓越奖，并入围2022年艾伯塔省科学、技术和领导力（ASTech）奖。在加入公司之前，Facchini博士是Epimeron公司、Willow Biosciences公司和MagicMed Industries公司的联合创始人和首席科学官。Facchini博士发表了170多篇同行评议的科学论文，并共同发明了涉及50多项专利的创新。Facchini博士是天然产物代谢生化和生物技术领域的国际领导者。
- Peter Facchini,has served as Enveric Biosciences, Inc. Chief Innovation Officer since joining the Company in September 2021. Dr. Facchini has been a Professor of Plant Biochemistry in the Department of Biological Sciences at the University of Calgary since 1995, during which he held the Canada Research Chair in Plant Metabolic Processes Biotechnology, was a 2019 Parex Resources Innovation Fellow, received the 2021 Faculty of Science Innovation Excellence Award, and was a finalist for the 2022 Alberta Science, Technology and Leadership (ASTech) award. Prior to joining the Company, Dr. Facchini co-founded and was the Chief Scientific Officer of Epimeron Inc., Willow Biosciences Inc. and MagicMed Industries Inc. Dr. Facchini has published over 170 peer-reviewed scientific papers and co-invented innovations covered by more than 50 patents. Dr. Facchini is an international leader in the fields of natural product metabolic biochemistry and biotechnology.
- Kevin Coveney
Kevin Coveney，自2023年3月13日起担任Enveric Biosciences, Inc.首席财务官。Coveney先生为公司带来了30多年的生物技术财务和会计经验。Coveney先生是Coveney Capital Advisors的创始人，曾分别于2022年9月至2023年3月和2022年10月至2023年3月为Progressive Therapeutics，Inc.和Power of Patients，LLC提供部分CFO和咨询服务。Coveney先生曾于2021年11月至2022年6月在Memgen公司担任首席财务官，并于2020年4月至2021年4月在Q-State Biosciences公司担任首席财务官。在担任首席财务官之前，Coveney先生于2018年11月至2020年2月担任Vedanta Biosciences，Inc.的财务、人力资源和IT高级副总裁。2015年9月至2018年11月，他在Berg Health LLC担任多个高级职位。Coveney先生于2007年7月至2012年10月担任Braver PC（现为Marcum）的审计合伙人。Coveney先生拥有马萨诸塞大学管理学学士学位，主修会计学，曾在美国海岸警卫队担任士官。
Kevin Coveney,has served as Enveric Biosciences, Inc. Chief Financial Officer since March 13, 2023.Mr. Coveney is the founder of Coveney Capital Advisors and has provided fractional CFO and consulting services to Progressive Therapeutics, Inc. from September 2022 to March 2023 and Power of Patients, LLC, from October 2022 to March 2023, respectively. Mr. Coveney previously held the position of chief financial officer at Memgen, Inc. from November 2021 to June 2022 and at Q-State Biosciences, Inc. from April 2020 to April 2021. Prior to his chief financial officer position, Mr. Coveney served as Senior Vice President of Finance, HR & IT of Vedanta Biosciences, Inc. from November 2018 to February 2020. He held various senior positions at Berg Health LLC from September 2015 to November 2018. Mr. Coveney was an Audit Partner at Braver PC (now Marcum) from July 2007 through October 2012. Mr. Coveney holds a Bachelor of Science degree in Management with a Concentration in Accounting from the University of Massachusetts and served as a non-commissioned officer in the United States Coast Guard.- Kevin Coveney，自2023年3月13日起担任Enveric Biosciences, Inc.首席财务官。Coveney先生为公司带来了30多年的生物技术财务和会计经验。Coveney先生是Coveney Capital Advisors的创始人，曾分别于2022年9月至2023年3月和2022年10月至2023年3月为Progressive Therapeutics，Inc.和Power of Patients，LLC提供部分CFO和咨询服务。Coveney先生曾于2021年11月至2022年6月在Memgen公司担任首席财务官，并于2020年4月至2021年4月在Q-State Biosciences公司担任首席财务官。在担任首席财务官之前，Coveney先生于2018年11月至2020年2月担任Vedanta Biosciences，Inc.的财务、人力资源和IT高级副总裁。2015年9月至2018年11月，他在Berg Health LLC担任多个高级职位。Coveney先生于2007年7月至2012年10月担任Braver PC（现为Marcum）的审计合伙人。Coveney先生拥有马萨诸塞大学管理学学士学位，主修会计学，曾在美国海岸警卫队担任士官。
- Kevin Coveney,has served as Enveric Biosciences, Inc. Chief Financial Officer since March 13, 2023.Mr. Coveney is the founder of Coveney Capital Advisors and has provided fractional CFO and consulting services to Progressive Therapeutics, Inc. from September 2022 to March 2023 and Power of Patients, LLC, from October 2022 to March 2023, respectively. Mr. Coveney previously held the position of chief financial officer at Memgen, Inc. from November 2021 to June 2022 and at Q-State Biosciences, Inc. from April 2020 to April 2021. Prior to his chief financial officer position, Mr. Coveney served as Senior Vice President of Finance, HR & IT of Vedanta Biosciences, Inc. from November 2018 to February 2020. He held various senior positions at Berg Health LLC from September 2015 to November 2018. Mr. Coveney was an Audit Partner at Braver PC (now Marcum) from July 2007 through October 2012. Mr. Coveney holds a Bachelor of Science degree in Management with a Concentration in Accounting from the University of Massachusetts and served as a non-commissioned officer in the United States Coast Guard.